As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress. While HPV vaccine efforts had the "benefit" of a viral source for the disease, other researchers are developing vaccines for cancers that are not virally based, in an effort to coax the immune system into attacking cancerous cells. Today at the 2007 Annual Meeting of the American Association for Cancer Research, presentations on ongoing HPV trials and other new approaches to stimulating the immune system are injecting momentum into cancer vaccine research.
Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine: Abstract 4900
Ongoing evaluation of a phase II trial of a human papillomavirus vaccine, developed to prevent cervical cancer, shows that the vaccine continues to protect against HPV types 16 and 18 at five and a half years into the study, according to researchers from the University of Louisville. Their findings also show that the vaccine offers significant cross-protection for HPV types 45 and 31.
The study follows 1113 women between the ages of 15 and 25 in North America and Brazil randomized to receive three doses of either the vaccine or the control. The vaccine, made by GlaxoSmithKline, which funded the study, is designed to protect against two strains of HPV, types 16 and 18, which together are thought to cause nearly 72 percent of all cases of cervical cancer.
At over five years into the study’s follow-up, the researchers found that approximately 98 percent of subjects still maintained protection against HPV types 16 and 18. Regardless of HPV status, the vaccine also appears to prevent most occurrences of cervical intraepithelial neoplasia lesions ?abnormal, precancerous cell growths found in the cervix.
'"/>Source:
American Association for Cancer Research
Page: 1 2 3 4 5 Related biology news :1.
Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer2.
Jump-starting T Cells In Skin Cancer3.
Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer4.
Fox Chase Cancer Center scientists identify immune-system mutation5.
Breakthrough Microarray-based Technology for the Study of Cancer6.
Yale Scientists Find MicroRNA Regulates Ras Cancer Gene7.
Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery8.
First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers9.
Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer10.
New Breast Cancer Test Could Save Lives11.
Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells